ArticleThe Journal of clinical investigation1999
Adenoviral cardiotrophin-1 gene transfer protects pmn mice from progressive motor neuronopathy.
Article in The Journal of clinical investigation, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 66 citations in OpenAlex.
- Investigation of Galectin-3 and Cardiotrophin-1 Concentrations as Biomarkers in Dogs with Neurological Distemper.Veterinary sciences · 2025Article
- Cardiotrophin-1 therapy reduces disease severity in a murine model of glomerular disease.Physiological reports · 2024Article
- Beyond Trophic Factors: Exploiting the Intrinsic Regenerative Properties of Adult Neurons.Frontiers in cellular neuroscience · 2019Review
- Fine-mapping of genes determining extrafusal fiber properties in murine soleus muscle.Physiological genomics · 2017Article
- Cardiotrophin-1 (CT-1) improves high fat diet-induced cognitive deficits in mice.Neurochemical research · 2015Article
- Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism.Oncoimmunology · 2012Article
- Therapy development for spinal muscular atrophy in SMN independent targets.Neural plasticity · 2012Review
- QTL Analysis of Type I and Type IIA Fibers in Soleus Muscle in a Cross between LG/J and SM/J Mouse Strains.Frontiers in genetics · 2011Article
- Tetanus toxin C-fragment: the courier and the cure?Toxins · 2010Review
- Inflammation in ALS and SMA: sorting out the good from the evil.Neurobiology of disease · 2010Review
- Cardiotrophin-1 maintains the undifferentiated state in skeletal myoblasts.The Journal of biological chemistry · 2009Article
- Progressive motor neuronopathy: a critical role of the tubulin chaperone TBCE in axonal tubulin routing from the Golgi apparatus.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
- Neuroprotective effects of cardiotrophin-like cytokine on retinal ganglion cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2005Article
- Therapeutic gene transfer to the nervous system using viral vectors.Journal of neurovirology · 2003Review
- Protective effects of adenoviral cardiotrophin-1 gene transfer on rubrospinal neurons after spinal cord injury in adult rats.Neurotoxicity research · 2003Article
- Dynamic pattern of reg-2 expression in rat sensory neurons after peripheral nerve injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2002Article
- Spinal muscular atrophy disease: a literature review for therapeutic strategies.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiotrophin-1 (CT-1), an IL-6-related cytokine, causes hypertrophy of cardiac myocytes and has pleiotropic effects on various other cell types, including motoneurons. Here, we analyzed systemic CT-1 effects in progressive motor neuronopathy (pmn) mice that suffer from progressive motoneuronal degeneration, muscle paralysis, and premature death. Administration of an adenoviral CT-1 vector to newborn pmn mice leads to sustained CT-1 expression in the injected muscles and bloodstream, prolonged survival of animals, and improved motor functions. CT-1-treated pmn mice showed a significantly reduced degeneration of facial motoneuron cytons and phrenic nerve myelinated axons. The terminal innervation of skeletal muscle, grossly disturbed in untreated pmn mice, was almost completely preserved in CT-1-treated pmn mice. The remarkable neuroprotection conferred by CT-1 might become clinically relevant if CT-1 side effects, including cardiotoxicity, could be circumvented by a more targeted delivery of this cytokine to the nervous system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.